Showing 25 to 36 of 36 results
Eli Lilly's Oral Semaglutide Shows Promise, Poised to Disrupt Weight-Loss Market
Eli Lilly's oral semaglutide, orforglipron, shows promising results with 14.7% average weight loss in phase two trials, prompting a $550 million revenue projection and expected launch next year, intensifying competition in the $25 billion global obesity drug market.
Eli Lilly's Oral Semaglutide Shows Promise, Poised to Disrupt Weight-Loss Market
Eli Lilly's oral semaglutide, orforglipron, shows promising results with 14.7% average weight loss in phase two trials, prompting a $550 million revenue projection and expected launch next year, intensifying competition in the $25 billion global obesity drug market.
Progress
48% Bias Score
France Secures Continued Wegovy Access Pending Price Negotiation
Novo Nordisk will continue providing free Wegovy to 3,000 French patients until at least December 2025 while negotiating a price for national reimbursement, following a positive review by the Haute Autorité de santé (HAS) in December 2024 and initial access for nearly 10,000 patients through an earl...
France Secures Continued Wegovy Access Pending Price Negotiation
Novo Nordisk will continue providing free Wegovy to 3,000 French patients until at least December 2025 while negotiating a price for national reimbursement, following a positive review by the Haute Autorité de santé (HAS) in December 2024 and initial access for nearly 10,000 patients through an earl...
Progress
32% Bias Score
Premarket Movers: Boeing, Novo Nordisk, Twilio Lead
Premarket trading saw significant stock movements: Boeing fell 1.3% due to disappointing Q4 results; Novo Nordisk jumped 14% following positive obesity drug trial data; Twilio rallied 18% on an optimistic future forecast; CSX dropped 3.5% on lower revenue; and Texas Instruments slumped 4% after a we...
Premarket Movers: Boeing, Novo Nordisk, Twilio Lead
Premarket trading saw significant stock movements: Boeing fell 1.3% due to disappointing Q4 results; Novo Nordisk jumped 14% following positive obesity drug trial data; Twilio rallied 18% on an optimistic future forecast; CSX dropped 3.5% on lower revenue; and Texas Instruments slumped 4% after a we...
Progress
32% Bias Score
Trump's Greenland Tariff Threat Could Hike Ozempic, Wegovy Prices
President-elect Trump's threat to impose high tariffs on Denmark unless it sells Greenland to the US could significantly increase the price of the popular diabetes and weight-loss drugs Ozempic and Wegovy, which are manufactured by Novo Nordisk. The US imported $5.7 billion in pharmaceuticals from D...
Trump's Greenland Tariff Threat Could Hike Ozempic, Wegovy Prices
President-elect Trump's threat to impose high tariffs on Denmark unless it sells Greenland to the US could significantly increase the price of the popular diabetes and weight-loss drugs Ozempic and Wegovy, which are manufactured by Novo Nordisk. The US imported $5.7 billion in pharmaceuticals from D...
Progress
40% Bias Score
Novo Nordisk Stock Plummets 40% on CagriSema Trial Results
Novo Nordisk's stock price has fallen 40% from its June high due to market correction following less-than-expected phase III trial results for its new obesity drug, CagriSema (20.4% weight reduction vs. projected 25%), which impacted investor confidence in its future growth projections and added to ...
Novo Nordisk Stock Plummets 40% on CagriSema Trial Results
Novo Nordisk's stock price has fallen 40% from its June high due to market correction following less-than-expected phase III trial results for its new obesity drug, CagriSema (20.4% weight reduction vs. projected 25%), which impacted investor confidence in its future growth projections and added to ...
Progress
40% Bias Score
France Approves Wegovy Reimbursement for Severely Obese Adults
France's Haute Autorité de Santé (HAS) approved Wegovy reimbursement for severely obese adults (BMI ≥35 kg/m²), following new data demonstrating reduced cardiovascular risks and approximately 17% weight loss; the drug, costing €274–€365 monthly, necessitates combined use with diet and exercise.
France Approves Wegovy Reimbursement for Severely Obese Adults
France's Haute Autorité de Santé (HAS) approved Wegovy reimbursement for severely obese adults (BMI ≥35 kg/m²), following new data demonstrating reduced cardiovascular risks and approximately 17% weight loss; the drug, costing €274–€365 monthly, necessitates combined use with diet and exercise.
Progress
36% Bias Score
Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments
Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.
Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments
Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.
Progress
36% Bias Score
Novo Nordisk Faces Scrutiny Over Undisclosed Millions in Payments
Novo Nordisk, the manufacturer of popular weight-loss drugs, failed to disclose £1.2 million in payments to healthcare organizations and misattributed an additional £338,435, prompting concerns about transparency and accountability within the pharmaceutical industry. Investigations revealed a patter...
Novo Nordisk Faces Scrutiny Over Undisclosed Millions in Payments
Novo Nordisk, the manufacturer of popular weight-loss drugs, failed to disclose £1.2 million in payments to healthcare organizations and misattributed an additional £338,435, prompting concerns about transparency and accountability within the pharmaceutical industry. Investigations revealed a patter...
Progress
40% Bias Score
LVMH Overtakes Novo Nordisk as Europe's Most Valuable Company
LVMH has overtaken Novo Nordisk as Europe's most valuable company, with a market cap of €341 billion versus Novo Nordisk's €261 billion, due to strong performance in the luxury sector and concerns about Novo Nordisk's pricing in the US.
LVMH Overtakes Novo Nordisk as Europe's Most Valuable Company
LVMH has overtaken Novo Nordisk as Europe's most valuable company, with a market cap of €341 billion versus Novo Nordisk's €261 billion, due to strong performance in the luxury sector and concerns about Novo Nordisk's pricing in the US.
Progress
36% Bias Score
Zepbound Poised to Exacerbate Healthcare Cost Increases
Eli Lilly's new anti-obesity drug, Zepbound, is projected to become a major cost driver for health insurers in 2025 due to its superior efficacy compared to existing GLP-1 drugs like Wegovy, adding to the already 1% increase in employer health costs caused by these drugs and raising premiums by 9% t...
Zepbound Poised to Exacerbate Healthcare Cost Increases
Eli Lilly's new anti-obesity drug, Zepbound, is projected to become a major cost driver for health insurers in 2025 due to its superior efficacy compared to existing GLP-1 drugs like Wegovy, adding to the already 1% increase in employer health costs caused by these drugs and raising premiums by 9% t...
Progress
40% Bias Score
Ozempic Linked to Doubled Risk of Rare Eye Disease
Two studies from the University of Southern Denmark reveal a doubled risk of developing a rare, irreversible eye disease among Ozempic users compared to non-users; health authorities are monitoring the situation closely.
Ozempic Linked to Doubled Risk of Rare Eye Disease
Two studies from the University of Southern Denmark reveal a doubled risk of developing a rare, irreversible eye disease among Ozempic users compared to non-users; health authorities are monitoring the situation closely.
Progress
44% Bias Score
Wegovy Launches in China
The weight-loss drug Wegovy launches in China, offering a potentially effective treatment for the country's large obese population, but also raising questions about affordability and healthcare systems.
Wegovy Launches in China
The weight-loss drug Wegovy launches in China, offering a potentially effective treatment for the country's large obese population, but also raising questions about affordability and healthcare systems.
Progress
40% Bias Score
Showing 25 to 36 of 36 results